Cargando…
HiJAKing Immunotherapy-Resistant Melanoma for a Cure
Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors c...
Autores principales: | Shi, Lewis Zhichang, Shen, Hongxing, Ojo, Oluwagbemiga A, Bonner, James A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020808/ https://www.ncbi.nlm.nih.gov/pubmed/36640142 http://dx.doi.org/10.1093/oncolo/oyac270 |
Ejemplares similares
-
HiJAKing Innate Lymphoid Cells?
por: Sciumè, Giuseppe, et al.
Publicado: (2017) -
β-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload
por: Melchiori, Luca, et al.
Publicado: (2010) -
Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling
por: Shen, Hongxing, et al.
Publicado: (2022) -
Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis
por: Shi, Lewis Zhichang, et al.
Publicado: (2021) -
Metabolic checkpoints in neurodegenerative T helper 17 (T(H)17) and neuroregenerative regulatory T (T(reg)) cells as new therapeutic targets for multiple sclerosis
por: Shen, Hongxing, et al.
Publicado: (2019)